"Photosensitizing Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms.
Descriptor ID |
D017319
|
MeSH Number(s) |
D27.505.954.444.600 D27.505.954.600.710
|
Concept/Terms |
Photosensitizing Effect- Photosensitizing Effect
- Effect, Photosensitizing
- Photosensitizing Effects
- Effects, Photosensitizing
|
Below are MeSH descriptors whose meaning is more general than "Photosensitizing Agents".
Below are MeSH descriptors whose meaning is more specific than "Photosensitizing Agents".
This graph shows the total number of publications written about "Photosensitizing Agents" by people in this website by year, and whether "Photosensitizing Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
2000 | 2 | 0 | 2 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 1 | 3 | 4 |
2005 | 2 | 2 | 4 |
2006 | 4 | 0 | 4 |
2007 | 1 | 0 | 1 |
2008 | 3 | 0 | 3 |
2010 | 1 | 0 | 1 |
2011 | 3 | 0 | 3 |
2012 | 1 | 0 | 1 |
2013 | 2 | 1 | 3 |
2014 | 1 | 1 | 2 |
2015 | 4 | 2 | 6 |
2016 | 1 | 3 | 4 |
2017 | 2 | 1 | 3 |
2018 | 2 | 0 | 2 |
2019 | 1 | 1 | 2 |
2020 | 2 | 3 | 5 |
2021 | 0 | 1 | 1 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Photosensitizing Agents" by people in Profiles.
-
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 09 01; 158(9):1031-1039.
-
Clinical impact of the worldwide shortage of verteporfin (Visudyne?) on ophthalmic care. Acta Ophthalmol. 2022 Nov; 100(7):e1522-e1532.
-
Simultaneous Exposure to Intracellular and Extracellular Photosensitizers for the Treatment of Staphylococcus aureus Infections. Antimicrob Agents Chemother. 2021 11 17; 65(12):e0091921.
-
5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. Sci Rep. 2020 10 14; 10(1):17237.
-
Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma. Dermatol Online J. 2020 Sep 15; 26(9).
-
Near-Infrared Light-Triggered Chlorine Radical (. Cl) Stress for Cancer Therapy. Angew Chem Int Ed Engl. 2020 11 16; 59(47):21032-21040.
-
Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivative-Mediated Intraperitoneal Photodynamic Therapy in a Canine Model. Photochem Photobiol. 2020 05; 96(3):684-691.
-
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res. 2020 07; 8(7):952-965.
-
Visible-Light-Activated Molecular Nanomachines Kill Pancreatic Cancer Cells. ACS Appl Mater Interfaces. 2020 Jan 08; 12(1):410-417.
-
Comparative Functional Outcomes After Corneal Crosslinking Using Standard, Accelerated, and Accelerated With Higher Total Fluence Protocols. Cornea. 2019 Apr; 38(4):433-441.